Elmind Capital LP Acquires Shares of 520,000 BioCryst Pharmaceuticals, Inc. $BCRX

Elmind Capital LP acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 520,000 shares of the biotechnology company’s stock, valued at approximately $5,200,000,000. BioCryst Pharmaceuticals comprises 1.3% of Elmind Capital LP’s holdings, making the stock its 19th largest holding. Elmind Capital LP owned 0.20% of BioCryst Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of BCRX. BlackRock Inc. bought a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at $238,930,000. RA Capital Management L.P. purchased a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at about $123,452,000. Deerfield Management Company L.P. grew its position in shares of BioCryst Pharmaceuticals by 159.4% during the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after purchasing an additional 7,477,000 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of BioCryst Pharmaceuticals by 7,807.2% in the fourth quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company’s stock worth $57,791,000 after purchasing an additional 7,310,745 shares during the last quarter. Finally, Perceptive Advisors LLC lifted its position in shares of BioCryst Pharmaceuticals by 135.1% in the first quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock worth $70,772,000 after buying an additional 4,271,504 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Get BioCryst Pharmaceuticals alerts:

BioCryst Pharmaceuticals Trading Up 1.5%

NASDAQ:BCRX opened at $9.83 on Wednesday. The company has a market cap of $2.51 billion, a price-to-earnings ratio of -6.55 and a beta of 0.56. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $11.22. The stock has a fifty day simple moving average of $9.66 and a 200-day simple moving average of $9.00.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The business had revenue of $218.25 million for the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The business’s revenue was up 33.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.15 EPS. As a group, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BCRX has been the subject of several research analyst reports. Wall Street Zen upgraded BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 8th. JPMorgan Chase & Co. assumed coverage on BioCryst Pharmaceuticals in a research report on Monday, July 13th. They set a “neutral” rating and a $12.00 target price for the company. Citizens Jmp raised their target price on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, May 7th. Wedbush decreased their price target on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Finally, Royal Bank Of Canada dropped their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $20.60.

Read Our Latest Report on BCRX

BioCryst Pharmaceuticals Profile

(Free Report)

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

See Also

• Five stocks we like better than BioCryst Pharmaceuticals
• Pathward’s Credit Scare Tests Its Comeback Story
• Wiring the AI Boom: Rumble’s $13.7B Pivot
• StoneX: Too Far Too Fast?
• DICK’s Sporting Goods Faces Pain Now for a Bigger Prize

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.